MedTrace Logo

Lactoferrin Treatment in HIV Patients

NCT01830595 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2024-12-31

Study results available
· View outcomes & findings →

Summary

Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.

Conditions

  • HIV Infection

Interventions

DRUG

Recombinant Lactoferrin

DRUG

Placebo

Sponsors & Collaborators

  • Ventria Bioscience

    collaborator INDUSTRY

  • Jason Baker

    lead OTHER

Principal Investigators

  • Jason V Baker, MD, MS · Hennepin Healthcare Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2017-07-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01830595 on ClinicalTrials.gov